Compare funds
Pick up to 10 funds. Compare funds from the same category for a fair reading.
Growth of ₹10,000
Basics
| Nippon India Nifty Pharma ETF | Nippon India ETF Nifty Midcap 150 | |
|---|---|---|
| Category | Equity ETFs | Equity ETFs |
| Plan | Direct | Direct |
| Fund house | Nippon India | Nippon India |
| NAV | ₹29.1863 | ₹235.6824 |
| NAV date | 20 Nov 2026 | 20 Nov 2026 |
| History | 5.4 years | 7.8 years |
| Expense ratio | 0.2% | 0.3% |
| Stars | Not rated | Not rated |
| Growth Score | — | — |
Returns
| Nippon India Nifty Pharma ETF | Nippon India ETF Nifty Midcap 150 | |
|---|---|---|
| 1 month | +10.82% | +5.97% |
| 3 months | +7.43% | −2.55% |
| 6 months | +14.54% | +1.72% |
| YTD | +25.40% | +2.66% |
| 1 year | +25.57% | +2.08% |
| 3 years (CAGR) | +22.02% | +13.87% |
| 5 years (CAGR) | +16.60% | +14.66% |
| 10 years (CAGR) | — | — |
| Since launch | +14.02% | +18.99% |
Risk
| Nippon India Nifty Pharma ETF | Nippon India ETF Nifty Midcap 150 | |
|---|---|---|
| Volatility | 15.0% | 18.3% |
| Downside volatility | 9.0% | 12.4% |
| Sharpe | 1.04 | 0.40 |
| Sortino | 1.72 | 0.59 |
| Calmar | 1.33 | 0.66 |
| Return / risk | 1.47 | 0.76 |
| Deepest fall | −20.98% | −38.35% |
| Days to recover | 136 | 228 |
| Below its high | −1.75% | −3.21% |
Against benchmark
| Nippon India Nifty Pharma ETF | Nippon India ETF Nifty Midcap 150 | |
|---|---|---|
| Alpha | +0.00% | +0.00% |
| Beta | 1.00 | 1.00 |
| R² | 100.0% | 100.0% |
| Up capture | 100.0% | 100.0% |
| Down capture | 100.0% | 100.0% |
| Tracking error | 0.0% | 0.0% |
| Information ratio | — | — |
| Treynor | 0.14 | 0.06 |
Consistency
| Nippon India Nifty Pharma ETF | Nippon India ETF Nifty Midcap 150 | |
|---|---|---|
| Best 1-year | +65.21% | +116.74% |
| Middle 1-year | +13.46% | +14.06% |
| Worst 1-year | −15.30% | −33.73% |
| 1-year periods with a loss | 25.8% | 11.6% |
| Middle 3-year | +20.51% | +24.17% |
| Positive months | 61.1% | 66.7% |
| Best day | +3.64% | +3.95% |
| Worst day | −4.03% | −7.10% |
| Worst 5% day | −1.62% | −2.00% |
| Positive days | 54.4% | 57.1% |
| NAVs a year | 248 | 248 |
SIP of ₹10,000 a month
| Nippon India Nifty Pharma ETF | Nippon India ETF Nifty Midcap 150 | |
|---|---|---|
| 5-year XIRR | +20.60% | +14.79% |
| 5-year value | ₹10,11,738 | ₹8,75,434 |
| 3-year XIRR | +19.58% | +7.85% |
| 1-year XIRR | +34.31% | +6.18% |
Holdings overlap i
| Nippon India Nifty Pharma ETF | Nippon India ETF Nifty Midcap 150 | |
|---|---|---|
| Nippon India Nifty Pharma ETF | — | 9% |
| Nippon India ETF Nifty Midcap 150 | 9% | — |
Share of money in the same stocks, by weight. Above 50% means much of one fund repeats the other.
Held by all of them
| Stock | Nippon India Nifty Pharma ETF | Nippon India ETF Nifty Midcap 150 |
|---|---|---|
| Laurus Labs Limited | 9.26% | 2.41% |
| Lupin Limited | 4.83% | 1.25% |
| Aurobindo Pharma Limited | 4.59% | 1.19% |
| Glenmark Pharmaceuticals Limited | 3.42% | 0.89% |
| Alkem Laboratories Limited | 3.05% | 0.79% |
| Mankind Pharma Limited | 2.79% | 0.73% |
| IPCA Laboratories Limited | 2.65% | 0.69% |
| Biocon Limited | 2.42% | 0.63% |
| Ajanta Pharma Limited | 1.58% | 0.41% |
| Abbott India Limited | 1.32% | 0.34% |
Sectors and company size
| Nippon India Nifty Pharma ETF | Nippon India ETF Nifty Midcap 150 | |
|---|---|---|
| Large companies | 45.3% | 5.9% |
| Mid companies | 47.1% | 90.7% |
| Small companies | 7.6% | 2.5% |
| Top 10 holdings | 78.6% | 18.4% |
| Largest sector | Pharmaceuticals & Biotechnology 100% | Pharmaceuticals & Biotechnology 10% |